Author

Monika J. Thielen

Observed names: Monika J Thielen, Monika Thielen

Observed institutions: Mayo Clinic, Duke University, University of South Florida, Dana-Farber Cancer Institute, University of Virginia

OpenAlex ID: A5017105146

Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

2011 · Anneke T. Schroen, Gina R. Petroni, et al. · Clinical Cancer Research · 73

Maternal and Newborn Hospital Outcomes of Perinatal SARS-CoV-2 Infection: A National Registry

2023 · Mark L. Hudak, Dustin D. Flannery, et al. · PEDIATRICS · 45

Ventilatory Assistance Before Umbilical Cord Clamping in Extremely Preterm Infants

2024 · Karen D. Fairchild, Gina R. Petroni, et al. · JAMA Network Open · 38

Research incentive program for clinical surgical faculty associated with increases in research productivity

2012 · Anneke T. Schroen, Monika J. Thielen, et al. · Journal of Thoracic and Cardiovascular Surgery · 32

Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials

2011 · Anneke T Schroen, Gina R Petroni, et al. · Clinical Trials · 22

Physiologic Transition During Delayed Cord Clamping With Assisted Ventilation in Preterm Infants

2025 · Jennifer L. Fang, Karen D. Fairchild, et al. · JAMA Network Open · 5

CCR Translation for This Article from Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

2023 · Anneke T. Schroen, Gina R. Petroni, et al.

Data from Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

2023 · Anneke T. Schroen, Gina R. Petroni, et al.

Data from Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

2023 · Anneke T. Schroen, Gina R. Petroni, et al.

CCR Translation for This Article from Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

2023 · Anneke T. Schroen, Gina R. Petroni, et al.

Works count: 10

Citation count: 215

H-index: 5

I10-index: 5